Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 2, 2014, Pages 76-79

  Aron, Jennifer L ^a   Gosselin, Robert ^b   Moll, Stephan ^c   Arkin, Charles F ^a   Mantha, Simon ^d  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AGED; APHASIA; ARTICLE; BIOASSAY; BRAIN HEMORRHAGE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFECT; EMERGENCY WARD; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; LEARNING DISORDER; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOPLASTIN TIME; TINNITUS; TREATMENT RESPONSE;

AGED; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; FACTOR VIIA; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN;

EID: 84894653920     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0913-0     Document Type: Article

References (10)

1. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116-1127. doi: 09-11-075810.1160/TH09-11-0758
2. Samama MM, Le Flem L, Guinet C, Gerotziafas G, Depasse F (2007) Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 5(12):2554-2556. doi: JTH275310.1111/j.1538-7836.2007.02753.x
3. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 107(5):985-997. doi: 10.1160/th11-11-0804
4. Dale B, Eikelboom JW, Weitz JI, Young E, Paikin JS, Coppens M, Whitlock RP, Connolly SJ, Ginsberg JS, Hirsh J (2012) Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis. doi: 10.1007/s11239-012-0857-9
5. Xu Y, Wu W, Wang L, Chintala M, Plump AS, Ogletree ML, Chen Z (2013) Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis. doi: 10.1097/MBC.0b013e32835e4219
6. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217-224. doi: 10.1160/TH12-03-0179
7. Davis PK, Musunuru H, Walsh M, Mitra R, Ploplis V, Castellino FJ (2012) The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine. Thromb Haemost 108(3):586-588. doi: 10.1160/TH12-04-0222
8. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119(9):2172-2174. doi: 119/9/217210.1182/blood-2011-11-393587
9. Garber ST, Sivakumar W, Schmidt RH (2012) Neurosurgical complications of direct thrombin inhibitors - catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 116(5):1093-1096. doi: 10.3171/2012.2.JNS112132
10. Livnat T, Martinowitz U, Zivelin A, Rima D, Kenet G (2011) A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. Thromb Haemost 105(4):688-695. doi: 10.1160/TH10-08-054210-08-0542